Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Believes Proposed Offer of $12.50 / Share Significantly Undervalues the Company and Does Not Adequately Compensate Shareholders for Exceptional Growth Ahead Does Not Intend to Vote For the Deal and ...

Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases.

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...